CSL Limited News - CSL

Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.

Expanded AFLURIA QUADRIVALENT age indication offers protection against four influenza virus strains for people five years of age and older...

Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas

Company Poised to Help Florida in the Wake of Hurricane Irma As hurricane recovery efforts continue in Texas, the U.S. Department of Health...

Une nouvelle étude de phase III montre une efficacité significativement plus grande chez les enfants de 6 mois à 24 moi...

Il a été démontré qu'aQIV offrait des avantages cliniques supplémentaires par rapport aux vaccins QIV contre la grippe ne contenant pas...

Une étude montre que les parents canadiens sont disposés à administrer à leurs nourrissons le vaccin contre la grippe ave...

Les taux canadiens actuels d'immunisation pédiatrique contre la grippe sont inférieurs aux objectifs de santé publique et doivent être...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

aQIV demonstrates additional clinical benefit over non-adjuvanted QIV influenza vaccine in children aged 6 to less than 24 months Annual...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

aQIV demonstrates additional clinical benefit over non-adjuvanted QIV influenza vaccine in children aged 6 to less than 24 months Annual...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CSL Limited (CSL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CSL News

Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.

Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas

Une nouvelle étude de phase III montre une efficacité significativement plus grande chez les enfants de 6 mois à 24 moi...

Une étude montre que les parents canadiens sont disposés à administrer à leurs nourrissons le vaccin contre la grippe ave...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

Canadian Parents Willing to Vaccinate Their Infants with Adjuvanted Influenza Vaccine, Study Finds

Seqirus anuncia avanços importantes em preparação para pandemias

Seqirus Announces Major Advances in Pandemic Preparedness

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market

Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology

Should you buy Australian Foundation Investment Co Ltd?

Australia Stocks Close Near Flat After Mixed Inflation Data

Australia Stocks End up Slightly as Key Inflation Data Looms

CSL Catches Cold from Flu Vaccines Deal with Novartis -- Market Talk

CSL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CSL Limited (CSL) News

CSL Limited (CSL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CSL News

Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.

Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas

Une nouvelle étude de phase III montre une efficacité significativement plus grande chez les enfants de 6 mois à 24 moi...

Une étude montre que les parents canadiens sont disposés à administrer à leurs nourrissons le vaccin contre la grippe ave...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQ...

Canadian Parents Willing to Vaccinate Their Infants with Adjuvanted Influenza Vaccine, Study Finds

Seqirus anuncia avanços importantes em preparação para pandemias

Seqirus Announces Major Advances in Pandemic Preparedness

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market

Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology

Should you buy Australian Foundation Investment Co Ltd?

Australia Stocks Close Near Flat After Mixed Inflation Data

Australia Stocks End up Slightly as Key Inflation Data Looms

CSL Catches Cold from Flu Vaccines Deal with Novartis -- Market Talk

CSL Discussion

Your Recent History